Drugs / NKTT120
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01783691 | Feb 2013 → May 2015 | sickle cell disease | NKT Therapeutics | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NKTT120 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01783691 ↗ |
| Action | Deplete | “NKTT120 produced rapid, specific and sustained iNKT cell depletion” PMID 28152086 ↗ Feb 2017 |
| Modality | Monoclonal antibody | “NKTT120 is an anti-iNKT cell monoclonal antibody” PMID 28152086 ↗ Feb 2017 |
| Route | Intravenous | “Intravenous NKTT120” NCT01783691 ↗ |